MAPT

Synonyms

MAPT, MTBT1, Paired helical filament-tau, MAPTL, Microtubule Associated Protein Tau, G Protein Beta1/Gamma2 Subunit-Interacting Factor 1, Protein Phosphatase 1, Regulatory Subunit 103, Neurofibrillary Tangle Protein, PHF-Tau, TAU, Microtubule-Associated Protein Tau, Isoform 4, Microtubule-Associated Protein Tau, PPP1R103, FTDP-17, MTBT2, DDPAC, MSTD, PPND, tau Proteins, MGC138549, FLJ31424

Description

Microtubule-associated protein tau can promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by TAU/MAPT localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization.

KO Status

F1 (+/-)

Drug Information

Launched drug: 1
Drugs in clinical trials: 29
Latest Research Phase: Approved

Drug Name

Code

Phase

Company

Indications

Clinical Trials

BEY-2153

BEY-2153

Beyondbio Inc

Flortaucipir F 18

T807, 18F-AV-1451, F-18-AV-1451

Approved

Siemens Medical Solution

Brain Injuries, Traumatic, Depression, Alzheimer Disease, Cognitive Dysfunction

Leuco methylthioninium

LMTM, L-MTx, LMT-X, TRX-0237, Leuco-MTx

Phase 3 Clinical

Taurx Pharmaceuticals

Alzheimer Disease, Dementia, Frontotemporal Dementia

PI-2620

PI-2620, 18F-PI-2620

Phase 3 Clinical

Piramal, Ac Immune

Supranuclear Palsy, Progressive, Cognitive Dysfunction, Alzheimer Disease

Semorinemab

RG-6100, MTAU-9937A, RO-7105705

Phase 2 Clinical

Ac Immune

Alzheimer Disease

[18F]THK-5117

[18F]THK-5117

Phase 2 Clinical

Tohoku University

Alzheimer Disease

Tilavonemab

C2N-8E12, ABBV-8E12

Phase 2 Clinical

C2n Diagnostics

Supranuclear Palsy, Progressive, Alzheimer Disease

APN-1607

[18F]PM-PBB3, APN-1607, 18F-PM-PBB3, 18F-APN-1607

Phase 2 Clinical

Aprinoia Therapeutics Ltd

Supranuclear Palsy, Progressive, Alzheimer Disease, Cognitive Dysfunction

FluoroTau

[18F]THK-5351, GE-216, F-18-THK-5351

Phase 2 Clinical

Tohoku University

Nerve Degeneration, Alzheimer Disease

Alzheimer's disease vaccine (Axon Neuroscience)

AADvac-1

Phase 2 Clinical

Axon Biochemicals

Alzheimer Disease, Primary Progressive Nonfluent Aphasia

References


Title

Authors

Source

Dephosphorylation of tau by protein phosphatase 5: impairment in Alzheimer's disease

Liu F., Iqbal K., Grundke-Iqbal I., Rossie S., Gong C.X.,

J. Biol. Chem. 280:1790-1796(2005)

Tau-tubulin kinase 1 (TTBK1), a neuron-specific tau kinase candidate, is involved in tau phosphorylation and aggregation

Sato S., Cerny R.L., Buescher J.L., Ikezu T.,

J. Neurochem. 98:1573-1584(2006)

Serum- and glucocorticoid-inducible kinase 1 (SGK1) increases neurite formation through microtubule depolymerization by SGK1 and by SGK1 phosphorylation of tau

Yang Y.C., Lin C.H., Lee E.H.,

Mol. Cell. Biol. 26:8357-8370(2006)

A probability-based approach for high-throughput protein phosphorylation analysis and site localization

Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.,

Nat. Biotechnol. 24:1285-1292(2006)

Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis

Hanger D.P., Byers H.L., Wray S., Leung K.-Y., Saxton M.J., Seereeram A., Reynolds C.H., Ward M.A., Anderton B.H.,

J. Biol. Chem. 282:23645-23654(2007)

Role for DYRK family kinases on regulation of apoptosis

Yoshida K.,

Biochem. Pharmacol. 76:1389-1394(2008)

Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis

Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III,

J. Proteome Res. 7:1346-1351(2008)

Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach

Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.,

Anal. Chem. 81:4493-4501(2009)

Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease

Liu F., Shi J., Tanimukai H., Gu J., Gu J., Grundke-Iqbal I., Iqbal K., Gong C.X.,

Brain 132:1820-1832(2009)

Hyperphosphorylation and aggregation of Tau in laforin-deficient mice, an animal model for Lafora disease

Puri R., Suzuki T., Yamakawa K., Ganesh S.,

J. Biol. Chem. 284:22657-22663(2009)